Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SZR001
MIFTS: 60

Sezary's Disease

Categories: Blood diseases, Cancer diseases, Rare diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Sezary's Disease

About this section

MalaCards integrated aliases for Sezary's Disease:

Name: Sezary's Disease 12 15 17
Sezary Syndrome 12 74 52 25 58 29 54 6 43 71
Sezary's Lymphoma 52 25
Sézary Syndrome 52 25
Sezary Erythroderma 25
Sezary Lymphoma 58
Sezary Disease 12

Characteristics:

Orphanet epidemiological data:

58
sezary syndrome
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: <1/1000000 (United States),<1/1000000 (Norway); Age of onset: Adult; Age of death: adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Skin diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare skin diseases
Rare haematological diseases


Sources

Summaries for Sezary's Disease

About this section
Genetics Home Reference : 25 Sézary syndrome is an aggressive form of a type of blood cancer called cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers characteristically affect the skin, causing different types of skin lesions. In Sézary syndrome, the cancerous T cells, called Sézary cells, are present in the blood, skin, and lymph nodes. A characteristic of Sézary cells is an abnormally shaped nucleus, described as cerebriform. People with Sézary syndrome develop a red, severely itchy rash (erythroderma) that covers large portions of their body. Sézary cells are found in the rash. However, the skin cells themselves are not cancerous; the skin problems result when Sézary cells move from the blood into the skin. People with Sézary syndrome also have enlarged lymph nodes (lymphadenopathy). Other common signs and symptoms of this condition include hair loss (alopecia), skin swelling (edema), thickened skin on the palms of the hands and soles of the feet (palmoplantar keratoderma), abnormalities of the fingernails and toenails, and lower eyelids that turn outward (ectropion). Some people with Sézary syndrome are less able to control their body temperature than people without the condition. The cancerous T cells can spread to other organs in the body, including the lymph nodes, liver, spleen, and bone marrow. In addition, affected individuals have an increased risk of developing another lymphoma or other type of cancer. Sézary syndrome most often occurs in adults over age 60 and usually progresses rapidly; historically, affected individuals survived an average of 2 to 4 years after development of the condition, although survival has improved with newer treatments. Although Sézary syndrome is sometimes referred to as a variant of another cutaneous T-cell lymphoma called mycosis fungoides, these two cancers are generally considered separate conditions.

MalaCards based summary : Sezary's Disease, also known as sezary syndrome, is related to cutaneous t cell lymphoma and exanthem, and has symptoms including pruritus An important gene associated with Sezary's Disease is BCL10 (BCL10 Immune Signaling Adaptor), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Gemcitabine and Oxaliplatin have been mentioned in the context of this disorder. Affiliated tissues include t cells, skin and bone, and related phenotypes are pruritus and dry skin

NIH Rare Diseases : 52 Sezary syndrome is an aggressive form of cutaneous T-cell lymphoma which is a group of disorders that occur when T-cells (a type of white blood cell ) become cancerous and affect the skin. It is characterized by a widespread red rash that may cover most of the body, the presence of cancerous T cells (called Sezary cells) in the blood, and abnormally enlarged lymph nodes . Other signs and symptoms may include intense itchiness, scaling and peeling of the skin; fever; weight loss; hair loss; outward turning of the eyelids (ectropion); palmoplantar keratoderma ; malformation of the nails; and hepatosplenomegaly . The exact cause of Sezary syndrome is currently unknown. Treatment varies based on the signs and symptoms present in each person and the severity of the condition.

Wikipedia : 74 Sezary disease is a type of cutaneous lymphoma that was first described by Albert Sezary. The affected... more...

Sources

Related Diseases for Sezary's Disease

About this section

Diseases related to Sezary's Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 376)
# Related Disease Score Top Affiliating Genes
1 cutaneous t cell lymphoma 33.2 IL5 IL4 IL2RA IL2 IFNG IFNA1
2 exanthem 31.4 TNFRSF1B IL2 CTLA4
3 graft-versus-host disease 31.3 IL2 IFNG CD28
4 herpes zoster 31.3 TNFRSF1B IL2 IFNG IFNA1
5 alopecia 31.3 IL4 IL2 IFNG CTLA4
6 primary cutaneous t-cell lymphoma 31.2 PLS3 IL2RA
7 dermatitis 31.1 IL5 IL4 IL2 IFNG CTLA4 CCR4
8 acute graft versus host disease 31.1 IL4 IL2RA IL2 IFNG
9 skin disease 31.1 TNFRSF1B MIR17 IL5 IL4 IL2 IFNG
10 adult t-cell leukemia 31.1 IL2RA IL2 CTLA4 CD7 CCR4
11 lichen planus 31.1 IL4 IL2 IFNG
12 allergic hypersensitivity disease 31.1 IL5 IL4 IL2 IFNG CTLA4 CCR4
13 diarrhea 31.0 IL5 IL2 IFNG IFNA1
14 peripheral nervous system disease 31.0 IL4 IL2 IFNG CTLA4
15 chickenpox 31.0 TNFRSF1B IL4 IL2 IFNG
16 diphtheria 31.0 IL5 IL4 IL2RA IL2 IFNG
17 leishmaniasis 31.0 IL5 IL4 IL2 IFNG CTLA4 CD28
18 ige responsiveness, atopic 31.0 IL5 IL4 IFNG
19 leukemia, chronic lymphocytic 31.0 MIR223 MIR17 IL4 IL2RA IL2 IFNA1
20 t-cell adult acute lymphocytic leukemia 30.9 IL2RA IL2 CD7
21 cutaneous leishmaniasis 30.9 IL5 IL4 IL2 IFNG CTLA4
22 contact dermatitis 30.9 IL5 IL4 IL2 IFNG CCR10
23 lymphoma, non-hodgkin, familial 30.9 TNFRSF1B MIR17 IL4 IL2RA IL2 DPP4
24 aspergillosis 30.8 TNFRSF1B IL5 IL4 IFNG
25 thrombocytopenia 30.8 IL4 IL2 IFNG IFNA1 CTLA4
26 psoriasis 30.8 TNFRSF1B MIR17 IL5 IL4 IL2RA IL2
27 systemic scleroderma 30.8 STAT4 MIR223 IL4 IFNG
28 uveitis 30.8 TNFRSF1B IL4 IL2RA IL2 IFNG CTLA4
29 visceral leishmaniasis 30.8 IL4 IL2 IFNG CD28
30 erythema multiforme 30.8 IL5 IL4 IL2 IFNG
31 food allergy 30.7 IL5 IL4 IFNG CTLA4
32 folliculitis 30.7 IL5 IL4 IL2RA IFNG
33 dermatitis, atopic 30.7 IL5 IL4 IL2RA IL2 IFNG DPP4
34 severe combined immunodeficiency 30.7 IL5 IL4 IL2RA IL2 IFNG DPP4
35 lymphopenia 30.7 IL4 IL2RA IL2 IFNG CTLA4 CD28
36 sarcoidosis 1 30.7 TNFRSF1B IL2RA IL2 IFNG CD28
37 immune deficiency disease 30.7 IL4 IL2RA IL2 IFNG IFNA1 CD28
38 hypereosinophilic syndrome 30.7 IL5 IL4 IL2RA IL2 IFNG IFNA1
39 alopecia areata 30.7 IL4 IL2RA IL2 IFNG CTLA4
40 hairy cell leukemia 30.7 IL2RA IL2 IFNA1
41 acute t cell leukemia 30.7 MIR17 CD7 BCL10
42 acquired immunodeficiency syndrome 30.7 TNFRSF1B IL2RA IL2 IFNG IFNA1
43 arthritis 30.7 TNFRSF1B STAT4 IL4 IFNG CTLA4 CD28
44 chronic graft versus host disease 30.7 IL2RA IFNG
45 myeloma, multiple 30.6 MIR342 MIR17 IL4 IL2 IFNG IFNA1
46 diabetes mellitus, insulin-dependent 30.5 IL4 IL2RA IL2 IFNG DPP4 CTLA4
47 mycosis fungoides 30.5 TNFRSF1B PLS3 IL5 IL2RA IL2 IFNG
48 toxoplasmosis 30.5 IL5 IL4 IFNG
49 toxic shock syndrome 30.5 IL4 IL2 IFNG
50 autoimmune disease 30.3 TNFRSF1B STAT4 IL5 IL4 IL2RA IL2

Graphical network of the top 20 diseases related to Sezary's Disease:



Diseases related to Sezary's Disease
Sources

Symptoms & Phenotypes for Sezary's Disease

About this section

Human phenotypes related to Sezary's Disease:

58 31 (show all 27)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pruritus 58 31 hallmark (90%) Very frequent (99-80%) HP:0000989
2 dry skin 58 31 hallmark (90%) Very frequent (99-80%) HP:0000958
3 neoplasm of the skin 58 31 hallmark (90%) Very frequent (99-80%) HP:0008069
4 lymphadenopathy 58 31 hallmark (90%) Very frequent (99-80%) HP:0002716
5 erythroderma 58 31 hallmark (90%) Very frequent (99-80%) HP:0001019
6 lichenification 58 31 hallmark (90%) Very frequent (99-80%) HP:0100725
7 cutaneous t-cell lymphoma 58 31 hallmark (90%) Very frequent (99-80%) HP:0012192
8 abnormal lymphocyte morphology 31 hallmark (90%) HP:0004332
9 splenomegaly 58 31 frequent (33%) Frequent (79-30%) HP:0001744
10 hepatomegaly 58 31 frequent (33%) Frequent (79-30%) HP:0002240
11 alopecia 58 31 frequent (33%) Frequent (79-30%) HP:0001596
12 immunodeficiency 58 31 frequent (33%) Frequent (79-30%) HP:0002721
13 palmoplantar keratoderma 58 31 frequent (33%) Frequent (79-30%) HP:0000982
14 nail dystrophy 58 31 frequent (33%) Frequent (79-30%) HP:0008404
15 tremor 58 31 occasional (7.5%) Occasional (29-5%) HP:0001337
16 abnormal facial shape 58 31 occasional (7.5%) Occasional (29-5%) HP:0001999
17 skeletal muscle atrophy 58 31 occasional (7.5%) Occasional (29-5%) HP:0003202
18 edema 58 31 occasional (7.5%) Occasional (29-5%) HP:0000969
19 peripheral neuropathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0009830
20 gangrene 58 31 occasional (7.5%) Occasional (29-5%) HP:0100758
21 abnormality of the pleura 58 31 occasional (7.5%) Occasional (29-5%) HP:0002103
22 irregular hyperpigmentation 58 31 occasional (7.5%) Occasional (29-5%) HP:0007400
23 abnormal immunoglobulin level 58 31 occasional (7.5%) Occasional (29-5%) HP:0010701
24 ectropion 58 31 occasional (7.5%) Occasional (29-5%) HP:0000656
25 abnormality of the face 58 Frequent (79-30%)
26 lymphoma 58 Very frequent (99-80%)
27 abnormality of lymphocytes 58 Very frequent (99-80%)

UMLS symptoms related to Sezary's Disease:


pruritus

GenomeRNAi Phenotypes related to Sezary's Disease according to GeneCards Suite gene sharing:

26 (show all 20)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-10 9.7 DPP4 IL4
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-109 9.7 DPP4
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.7 IFNA1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-14 9.7 IFNA1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 9.7 IFNA1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.7 CCR10
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-17 9.7 IL4
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-175 9.7 IFNA1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 9.7 CCR10
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-195 9.7 IFNA1
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-209 9.7 IFNA1
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.7 IL4
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-22 9.7 IL4
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.7 IFNA1
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 9.7 IL4
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-61 9.7 CCR10 DPP4 IFNA1 IL4
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-79 9.7 IFNA1
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-86 9.7 CCR10
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 9.7 DPP4
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 9.7 DPP4

MGI Mouse Phenotypes related to Sezary's Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.03 BCL10 CCR10 CD28 CD7 CTLA4 DPP4
2 hematopoietic system MP:0005397 10 BCL10 CCR10 CCR4 CD28 CD7 CTLA4
3 digestive/alimentary MP:0005381 9.92 CD28 CTLA4 IFNG IL2 IL2RA IL4
4 immune system MP:0005387 9.8 BCL10 CCR10 CCR4 CD28 CD7 CTLA4
5 respiratory system MP:0005388 9.23 CCR4 CTLA4 IFNG IL2 IL2RA IL4
Sources

Drugs & Therapeutics for Sezary's Disease

About this section

Drugs for Sezary's Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 304)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 4 95058-81-4 60750
2
Oxaliplatin Approved, Investigational Phase 4 61825-94-3 5310940 9887054 6857599 43805
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
4
Cisplatin Approved Phase 4 15663-27-1 84093 441203 2767
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
6
Cytarabine Approved, Experimental, Investigational Phase 4 147-94-4, 65-46-3 6253
7
Etoposide Approved Phase 4 33419-42-0 36462
8
Vincristine Approved, Investigational Phase 4 2068-78-2, 57-22-7 5978
9
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
10
rituximab Approved Phase 4 174722-31-7 10201696
11
Ifosfamide Approved Phase 4 3778-73-2 3690
12
Epirubicin Approved Phase 4 56420-45-2 41867
13 Thymoglobulin Phase 4
14 Antibodies, Monoclonal Phase 4
15 Immunoglobulins Phase 4
16 Antibodies Phase 4
17 BB 1101 Phase 4
18 Etoposide phosphate Phase 4
19
Isophosphamide mustard Phase 4 0
20 Orange Approved Phase 3
21
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
22
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
23
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
24
Ofloxacin Approved Phase 3 82419-36-1 4583
25
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
26
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
27
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 468682 2826718
28
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
29
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
30
Thiotepa Approved, Investigational Phase 2, Phase 3 52-24-4 5453
31
Acyclovir Approved Phase 3 59277-89-3 2022
32
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
33
Captopril Approved Phase 3 62571-86-2 44093
34
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
35
Naloxone Approved, Vet_approved Phase 3 465-65-6 5284596
36
Methoxsalen Approved Phase 3 298-81-7 4114
37
Bexarotene Approved, Investigational Phase 3 153559-49-0 82146
38
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
39
Moxifloxacin Approved, Investigational Phase 3 151096-09-2, 354812-41-2 152946
40
Polyestradiol phosphate Approved Phase 3 28014-46-2
41
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
42
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
43
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
44 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
45 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
46 Anesthetics, Dissociative Phase 3
47 Antiviral Agents Phase 3
48 Narcotics Phase 3
49 Analgesics Phase 3
50 Antiparasitic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 356)
# Name Status NCT ID Phase Drugs
1 A Multicenter Open-Label Study to Evaluate the Safety and Efficacy of DAB389IL-2 in Cutaneous T-Cell Lymphoma (CTCL) Patients Following Protocol 93-04-10, Protocol 93-04-11, or Protocol 92-04-01 or Who Meet the Requirements for Protocol 93-04-11 Except Have Biopsy-Documented CTCL That Does Not Express CD25 Completed NCT00051012 Phase 4 ONTAK
2 A Multicenter Phase III Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy of Two Dose Levels of DAB389IL-2 (9 and 18 Mcg/kg/Day) in Cutaneous T-Cell Lymphoma (CTCL) Patients With Stage Ia-III Disease Who, Following Less Than or Equal to 3 Previous Therapies, Have Recurrent or Persistent Disease That Has Been Biopsy-Documented to Express CD25 Completed NCT00050999 Phase 4 ONTAK
3 Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China Recruiting NCT02938741 Phase 4 Anti－human Thymoglobulin;Placebo
4 Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Not yet recruiting NCT04134247 Phase 4 PD-1 combined with chemotherapy;chemotherapy
5 Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome Terminated NCT01625455 Phase 4 Aprepitant;Placebo
6 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
7 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
8 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
9 A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma Completed NCT00425555 Phase 2, Phase 3 Panobinostat
10 A Phase II Study of Oral LBH589 in Adult Patients With Cutaneous T-Cell Lymphoma Who Are Intolerant to or Have Progressed on or After Prior HDAC Inhibitor Completed NCT00490776 Phase 2, Phase 3 LBH589
11 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
12 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
13 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
14 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
15 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
16 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
17 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
18 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
19 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
20 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
21 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
22 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT00438958 Phase 3
23 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
24 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
25 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
26 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
27 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
28 A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma Recruiting NCT02811783 Phase 3 Naloxone Hydrochloride Lotion, 0.5%;Placebo Lotion
29 Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma Active, not recruiting NCT01728805 Phase 3 Vorinostat
30 A Phase III Study of Lenalidomide Maintenance After Debulking Therapy in Patients With Advanced Cutaneous T-Cell Lymphoma Terminated NCT01098656 Phase 3 lenalidomide
31 Open Label, Dose Escalation, Followed by Open Label,Single Arm Clinical Trial of HuMax-CD4 in Patients With Mycosis Fungoides Type CTCL (Stage IB-IVB) or Sezary Syndrome Who Are Refractory or Intolerant to Targretin® (Bexarotene) and One Other Standard Therapy Terminated NCT00127881 Phase 3 HuMax-CD4 (zanolimumab)
32 A Randomized, Open-Label Phase III Trial to Evaluate the Efficacy and Safety of Bexarotene (Targretin) Capsules Combined With PUVA, Compared to PUVA Treatment Alone in Patients With Mycosis Fungoides Terminated NCT00056056 Phase 3 bexarotene;methoxypsoralen
33 Diffuse Large B Cell And Peripheral T Cell Non-Hodgkin's Lymphomas (NHL) In The Elderly. Influence Of Prolonged Oral Etoposide Added To CHOP Combination Chemotherapy In Patients With Good Physiological Status. An EORTC Randomized Phase II-III Trial Including Geriatric Assessment And Quality Of Life Terminated NCT00060385 Phase 2, Phase 3 CHOP regimen;EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
34 Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
35 Progression Free Survival (PFS) Comparison Between Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat TM) in Combination With Bortezomib (Velcade TM) and SAHA Alone in Refractory or Recurrent Advanced CTCL. A Randomized Study. Withdrawn NCT01386398 Phase 3 bortezomib;vorinostat
36 Phase II Study of Alemtuzumab in Patients With Advanced Mycosis Fungoides/Sezary Syndrome Unknown status NCT00157274 Phase 2 alemtuzumab
37 A Muliticenter, Dose-Reandomized Evaluation Of Targretin Capsules Plus PUVA In Patients With Stage IB - IIA Cutaneous T-Cell Lymphoma Unknown status NCT00030589 Phase 2 bexarotene;methoxsalen
38 PROTOCOL FOR THE MANAGEMENT OF MYCOSIS FUNGOIDES AND THE SEZARY SYNDROME Unknown status NCT00002557 Phase 2 CHOP regimen;doxorubicin hydrochloride;etoposide;leucovorin calcium;methotrexate
39 Non-Ablative Chemotherapeutic Conditioning Before Allogeneic Stem Cell Transplantation Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
40 A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy Unknown status NCT01075321 Phase 1, Phase 2 everolimus;lenalidomide
41 A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients With CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
42 Transplantation Using Umbilical Cord And Placental Blood Unknown status NCT00008164 Phase 2
43 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
44 Phase II Trial Of Campath-1H In Patients With Relapsed/Refractory Advanced Mycosis Fungoides or Sezary Syndrome Completed NCT00057967 Phase 2
45 Exploratory Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level Completed NCT01396070 Phase 2 Brentuximab vedotin
46 A Phase 2 Study of MK-3475 for the Treatment of Relapsed/Refractory Mycosis Fungoides/Sezary Syndrome Completed NCT02243579 Phase 2
47 Phase II Trial of Tretinoin (TRA) in Patients With Mycosis Fungoides/Sezary Syndrome Completed NCT00002479 Phase 2 tretinoin
48 Phase II Trial of Doxorubicin HCl Liposome Injection (Doxil®) in Advanced Stage Cutaneous T-Cell Lymphoma Followed by Bexarotene (Targretin®) Completed NCT00255801 Phase 2 Targretin® (bexarotene);pegylated liposomal doxorubicin hydrochloride
49 A Phase II Study of Bortezomib (VELCADE®) in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL) Completed NCT00182637 Phase 2 bortezomib
50 Phase II Evaluation of Immunization Against Tumor Cells in Subjects With Sezary Syndrome Using Autologous Mature Dendritic Cells Completed NCT00099593 Phase 2

Search NIH Clinical Center for Sezary's Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b

Cochrane evidence based reviews: sezary syndrome

Sources

Genetic Tests for Sezary's Disease

About this section

Genetic tests related to Sezary's Disease:

# Genetic test Affiliating Genes
1 Sezary Syndrome 29
Sources

Anatomical Context for Sezary's Disease

About this section

MalaCards organs/tissues related to Sezary's Disease:

40
T Cells, Skin, Bone, Bone Marrow, Lymph Node, B Cells, Liver
Sources

Publications for Sezary's Disease

About this section

Articles related to Sezary's Disease:

(show top 50) (show all 497)
# Title Authors PMID Year
1
MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential. 61 46
20448109 2010
2
Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. 6
9989495 1999
3
Differential CCR4 expression and function in cutaneous T-cell lymphoma cell lines. 54 61
19239991 2008
4
Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma. 54 61
18569641 2008
5
Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndrome. 54 61
17975162 2007
6
Bexarotene blunts malignant T-cell chemotaxis in Sezary syndrome: reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokine. 54 61
17546636 2007
7
Molecular analysis of T-cell receptor beta genes in cutaneous T-cell lymphoma reveals Jbeta1 bias. 54 61
16741518 2006
8
CCR10 is expressed in cutaneous T-cell lymphoma. 54 61
15700309 2005
9
Circulating clonal CLA(+) and CD4(+) T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7. 54 61
15727636 2005
10
Aberrant expression of T-plastin in Sezary cells. 54 61
14612505 2003
11
Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. 54 61
12393503 2003
12
Diminished expression of the type II receptor for TGFbeta (TGFbetaRII) in T lymphocytes from patients with Sezary syndrome is not due to mutations in the receptor's poly-A tract: limitations of the standard RT-PCR in cDNA sequence analysis of homopolymeric base stretches. 54 61
12546068 2002
13
Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. 54 61
11368440 2001
14
Chromosomally clonal T cells in the skin, blood, or lymph nodes of two Sezary syndrome patients express CD45RA, CD45RO, CDw150, and interleukin-4, but no interleukin-2 or interferon-gamma. 54 61
11168816 2001
15
Interleukin 7 (IL-7) receptor-specific cell killing by DAB389 IL-7: a novel agent for the elimination of IL-7 receptor positive cells. 54 61
9548535 1998
16
Hypertriglyceridemia during long-term interferon-alpha therapy in a series of hematologic patients. 54 61
9181461 1997
17
Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. 54 61
8799169 1996
18
The clonal nature of circulating Sezary cells. 54 61
7492785 1995
19
Keratinocyte interleukin-10 expression is upregulated in tape-stripped skin, poison ivy dermatitis, and Sezary syndrome, but not in psoriatic plaques. 54 61
7923918 1994
20
Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study. 54 61
8080984 1994
21
Survival in Mycosis Fungoides and Sezary Syndrome: How Can We Predict Outcome? 61
31980062 2020
22
Haploidentical hematopoietic cell transplantation for mycosis fungoides/Sezary syndrome. 61
31452419 2020
23
Low-dose total skin electron beam therapy: Quality of life improvement and clinical impact of maintenance and adjuvant treatment in patients with mycosis fungoides or Sezary syndrome. 61
31591658 2020
24
[Ulceration of lymphomatous skin lesions in a patient with Sezary syndrome treated with brentuximab-vedotin]. 61
31959414 2020
25
Hepatic Infiltration with Malignant T-cells Manifesting as Impending Acute Liver Failure in Sezary Syndrome. 61
31934317 2020
26
[Atypical Sézary syndrome in a young subject]. 61
31806381 2019
27
Heterogeneity of T-cell receptor expression at transformation in mycosis fungoides/Sezary Syndrome (MF/SS). 61
31629155 2019
28
The clinico-pathological spectrum of primary cutaneous lymphoma other than mycosis fungoides/Sezary syndrome. 61
31781845 2019
29
Preclinical Evidence for Targeting PI3K/mTOR Signaling with Dual-Inhibitors as a Therapeutic Strategy against Cutaneous T-Cell Lymphoma. 61
31682844 2019
30
Lack of Durable Remission with Conventional-Dose Total Skin Electron Therapy for the Management of Sezary Syndrome and Multiply Relapsed Mycosis Fungoides. 61
31717353 2019
31
Usefulness of Flow Cytometry for the Detection of Cutaneous Localization in Malignant Hematologic Disorders. 61
31050147 2019
32
Loss of β-arrestin-2 gene and possible functional consequences on Sezary Syndrome. 61
31106661 2019
33
Merkel cell carcinoma arising in association with cutaneous T-cell lymphoma: A potential diagnostic pitfall. 61
30561044 2019
34
Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. 61
29947731 2019
35
Extranodal lymphomas in the public health system in Chile: Analysis of 1251 patients from the National Adult Cancer Program. 61
30117170 2019
36
Clinical application of Total Skin Electron Beam (TSEB) therapy for the management of T cell cutaneous lymphomas. The evolving role of low dose (12 Gy) treatment schedule. 61
30582018 2019
37
Sézary Syndrome, recent biomarkers and new drugs. 61
30525758 2019
38
Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma. 61
30529073 2019
39
Successful treatment of Sezary syndrome with extracorporeal photopheresis - The first attempt in India. 61
31360016 2019
40
Molecular and Genomic Landscape of Peripheral T-Cell Lymphoma. 61
30596212 2019
41
Durable Control of Mycosis Fungoides after Sepsis: "Coley's Toxin?" Case Report and Review of the Literature. 61
31467737 2019
42
Primary Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sezary Syndrome. 61
30596221 2019
43
[Primary cutaneous lymphoma-a case series of 163 patients]. 61
29881891 2018
44
Hypo-pigmented mycosis fungoides is a rare malignancy in pediatrics. 61
30695982 2018
45
Health-related quality of life in patients with cutaneous T-cell lymphoma? 61
30074622 2018
46
Developments in the understanding of blood involvement and stage in mycosis fungoides/Sezary syndrome. 61
30017383 2018
47
Long-term complete remission of early hematological relapse after discontinuation of immunosuppressants following allogeneic transplantation for Sezary syndrome. 61
30283619 2018
48
[Importance of phototherapy in the treatment of chronic pruritus]. 61
30006661 2018
49
Adult T-cell leukemia/lymphoma can be indistinguishable from other more common T-cell lymphomas. The University of Miami experience with a large cohort of cases. 61
29449683 2018
50
Large Cell Transformation of Oral Mycosis Fungoides. 61
28741231 2018
Sources

Variations for Sezary's Disease

About this section

ClinVar genetic disease variations for Sezary's Disease:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 BCL10 NM_003921.5(BCL10):c.428del (p.Phe143fs)deletion Pathogenic 6260 rs587776632 1:85733584-85733584 1:85267901-85267901

Cosmic variations for Sezary's Disease:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM87675933 KMT2D haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.12655C>T p.Q4219* 12:49032050-49032050 0

Copy number variations for Sezary's Disease from CNVD:

7 (show top 50) (show all 353)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 38537 10 103280000 105830000 Deletion ACTR1A Sezary syndrome
2 38538 10 103280000 105830000 Deletion ARL3 Sezary syndrome
3 38539 10 103280000 105830000 Deletion BTRC Sezary syndrome
4 38540 10 103280000 105830000 Deletion COL17A1 Sezary syndrome
5 38541 10 103280000 105830000 Deletion CYP17A1 Sezary syndrome
6 38542 10 103280000 105830000 Deletion FGF8 Sezary syndrome
7 38543 10 103280000 105830000 Deletion LDB1 Sezary syndrome
8 38544 10 103280000 105830000 Deletion MGEA5 Sezary syndrome
9 38545 10 103280000 105830000 Deletion NEURL Sezary syndrome
10 38546 10 103280000 105830000 Deletion NFKB2 Sezary syndrome
11 38547 10 103280000 105830000 Deletion NT5C2 Sezary syndrome
12 38548 10 103280000 105830000 Deletion PCGF6 Sezary syndrome
13 38549 10 103280000 105830000 Deletion PDCD11 Sezary syndrome
14 38550 10 103280000 105830000 Deletion POLL Sezary syndrome
15 38551 10 103280000 105830000 Deletion PSD Sezary syndrome
16 38552 10 103280000 105830000 Deletion SH3PXD2A Sezary syndrome
17 38553 10 103280000 105830000 Deletion SLK Sezary syndrome
18 38554 10 103280000 105830000 Deletion SUFU Sezary syndrome
19 38555 10 103280000 105830000 Deletion TLX1 Sezary syndrome
20 38556 10 103280000 105830000 Deletion TRIM8 Sezary syndrome
21 39119 10 110240000 112960000 Deletion ADD3 Sezary syndrome
22 39120 10 110240000 112960000 Deletion DUSP5 Sezary syndrome
23 39121 10 110240000 112960000 Deletion MXI1 Sezary syndrome
24 39122 10 110240000 112960000 Deletion PDCD4 Sezary syndrome
25 39123 10 110240000 112960000 Deletion SMC3 Sezary syndrome
26 39709 10 118690000 123210000 Deletion BAG3 Sezary syndrome
27 39710 10 118690000 123210000 Deletion BRWD2 Sezary syndrome
28 39711 10 118690000 123210000 Deletion CASC2 Sezary syndrome
29 39712 10 118690000 123210000 Deletion EIF3S10 Sezary syndrome
30 39713 10 118690000 123210000 Deletion EMX2 Sezary syndrome
31 39714 10 118690000 123210000 Deletion FGFR2 Sezary syndrome
32 39715 10 118690000 123210000 Deletion GFRA1 Sezary syndrome
33 39716 10 118690000 123210000 Deletion HSPA12A Sezary syndrome
34 39717 10 118690000 123210000 Deletion INPP5F Sezary syndrome
35 39718 10 118690000 123210000 Deletion NANOS1 Sezary syndrome
36 39719 10 118690000 123210000 Deletion PRDX3 Sezary syndrome
37 39720 10 118690000 123210000 Deletion PRLHR Sezary syndrome
38 39721 10 118690000 123210000 Deletion RGS10 Sezary syndrome
39 39722 10 118690000 123210000 Deletion TIAL1 Sezary syndrome
40 40284 10 126610000 131820000 Deletion ADAM12 Sezary syndrome
41 40285 10 126610000 131820000 Deletion BCCIP Sezary syndrome
42 40286 10 126610000 131820000 Deletion CTBP2 Sezary syndrome
43 40287 10 126610000 131820000 Deletion DHX32 Sezary syndrome
44 40288 10 126610000 131820000 Deletion DOCK1 Sezary syndrome
45 40289 10 126610000 131820000 Deletion MGMT Sezary syndrome
46 40290 10 126610000 131820000 Deletion MKI67 Sezary syndrome
47 40291 10 126610000 131820000 Deletion MMP21 Sezary syndrome
48 40292 10 126610000 131820000 Deletion PTPRE Sezary syndrome
49 40293 10 126610000 131820000 Deletion ZRANB1 Sezary syndrome
50 42175 10 29840000 33170000 Deletion ARHGAP12 Sezary syndrome
Sources

Expression for Sezary's Disease

About this section
Search GEO for disease gene expression data for Sezary's Disease.
Sources

Pathways for Sezary's Disease

About this section

Pathways related to Sezary's Disease according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 63
Show member pathways
 13.79 TNFRSF1B STAT4 IL5 IL4 IL2RA IL2
2
PEDF Induced Signaling 63
Show member pathways
 13.67 TNFRSF1B IL5 IL4 IL2RA IL2 IFNG
3
TGF-Beta Pathway 63
Show member pathways
 13.5 TNFRSF1B STAT4 IL5 IL4 IL2RA IL2
4
Akt Signaling 63
Show member pathways
 13.39 TNFRSF1B STAT4 IL5 IL4 IL2RA IL2
5
Cytokine Signaling in Immune system 65
Show member pathways
 13.32 TNFRSF1B IL5 IL4 IL2RA IL2 IFNG
6
PAK Pathway 63
Show member pathways
 13.29 TNFRSF1B IL5 IL4 IL2RA IL2 CD28
7
Pathways in cancer 36
12.84 STAT4 IL5 IL4 IL2RA IL2 IFNG
8
Allograft rejection 1 36
Show member pathways
 12.83 IL5 IL4 IL2RA IL2 IFNG IFNA1
9
Measles 36
Show member pathways
 12.77 IL2RA IL2 IFNG IFNA1 CD28
10
Immune response NFAT in immune response 22
Show member pathways
 12.64 TNFRSF1B IL4 IL2RA IL2 IFNG CD28
11
T cell receptor signaling pathway 36
Show member pathways
 12.6 IL5 IL4 IL2 IFNG CTLA4 CD28
12
Th17 cell differentiation 36
Show member pathways
 12.58 STAT4 IL5 IL4 IL2RA IL2 IFNG
13
ICos-ICosL Pathway in T-Helper Cell 63
Show member pathways
 12.39 IL2RA IL2 CTLA4 CD28 BCL10
14
NF-kappaB Signaling 4
12.37 TNFRSF1B STAT4 IL4 IL2RA IL2 IFNG
15
Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.34 TNFRSF1B IL2RA IL2 CCR4 CCR10
16
JAK-STAT signaling pathway (KEGG) 36
Show member pathways
 12.31 STAT4 IL5 IL4 IL2RA IL2 IFNG
17
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.27 IL5 IL4 IL2RA IL2 IFNG IFNA1
18
Th1 Differentiation Pathway 64
Show member pathways
 12.06 STAT4 IL2 IFNG CD28
19
IL12-mediated signaling events 1
Show member pathways
 12 STAT4 IL4 IL2RA IL2 IFNG
20
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
12 IL5 IL4 IL2RA IL2 IFNG CD28
21
Hematopoietic cell lineage 36
11.91 IL5 IL4 IL2RA CD7
22
Jak-Stat Signaling Pathway (sino) 66
11.9 STAT4 IL2RA IL2 IFNG IFNA1
23
Rheumatoid arthritis 36
11.82 IFNG CTLA4 CD28
24
Glucocorticoid receptor regulatory network 1
11.81 IL5 IL4 IL2 IFNG
25
Innate Lymphoid Cell Differentiation Pathways 64
11.75 IL5 IL4 IL2RA IL2 IFNG CD7
26
Microglia Activation During Neuroinflammation: Microglia Polarization 64
11.68 IL4 IL2 IFNG
27
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.68 IL5 IL4 IL2RA IL2 IFNG CTLA4
28
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.66 STAT4 IL2RA IL2 IFNG
29
IL2 signaling events mediated by PI3K 1
Show member pathways
 11.65 IL4 IL2RA IL2
30
Development and heterogeneity of the ILC family 1
11.32 IL5 IL4 IFNG
31
T-Cell Receptor and Co-stimulatory Signaling 1
11.31 IL2 CTLA4 CD28
32
Cytokines and Inflammatory Response 1
11.29 IL5 IL4 IL2 IFNG
33
Immune response_IL-12 signaling pathway 22
Show member pathways
 11.27 STAT4 IL2RA IFNG
34
OX40 Pathway 63
11.19 IL5 IL4 IL2 IFNG
35
Th2 Differentiation Pathway 64
11.16 STAT4 IL5 IL4 IL2RA IL2 IFNG
36
IL12 signaling mediated by STAT4 1
11.1 STAT4 IL2RA IL2 IFNG CD28
37
Inflammatory Response Pathway 1
10.69 TNFRSF1B IL5 IL4 IL2RA IL2 IFNG
Sources

GO Terms for Sezary's Disease

About this section

Cellular components related to Sezary's Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 MIR342 MIR223 MIR17 IL5 IL4 IL2
2 external side of plasma membrane GO:0009897 9.35 IL2RA CTLA4 CD28 CCR4 CCR10
3 protein complex involved in cell adhesion GO:0098636 8.62 CTLA4 CD28

Biological processes related to Sezary's Disease according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.02 IL2RA IL2 CTLA4 CD7 CD28 BCL10
2 adaptive immune response GO:0002250 9.91 IL2 IFNG IFNA1 CTLA4 CD7 BCL10
3 cell surface receptor signaling pathway GO:0007166 9.9 TNFRSF1B IL2RA IFNG CD28
4 negative regulation of inflammatory response GO:0050728 9.8 TNFRSF1B MIR223 IL2RA IL2
5 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.76 IL4 IL2 IFNG
6 humoral immune response GO:0006959 9.75 IFNG IFNA1 CD28
7 T cell costimulation GO:0031295 9.73 DPP4 CTLA4 CD28
8 positive regulation of T cell proliferation GO:0042102 9.71 IL4 IL2RA IL2 CD28
9 cytokine-mediated signaling pathway GO:0019221 9.7 TNFRSF1B STAT4 IL5 IL4 IL2RA IL2
10 positive regulation of B cell proliferation GO:0030890 9.69 IL5 IL4 IL2
11 positive regulation of T cell differentiation GO:0045582 9.63 IL4 IL2RA IL2
12 negative regulation of immune response GO:0050777 9.62 IL2RA CTLA4
13 negative regulation of neuroinflammatory response GO:0150079 9.62 TNFRSF1B IL4
14 positive regulation of immunoglobulin secretion GO:0051024 9.61 IL5 IL2
15 interleukin-2-mediated signaling pathway GO:0038110 9.61 IL2RA IL2
16 positive regulation of MHC class II biosynthetic process GO:0045348 9.59 IL4 IFNG
17 negative regulation of lymphocyte proliferation GO:0050672 9.57 IL2RA IL2
18 T cell activation GO:0042110 9.56 IL4 DPP4 CD7 CD28
19 neuroinflammatory response GO:0150076 9.54 IL4 IFNG
20 regulation of T cell proliferation GO:0042129 9.54 TNFRSF1B CTLA4 CD28
21 positive regulation of cellular respiration GO:1901857 9.52 IL4 IFNG
22 positive regulation of isotype switching to IgG isotypes GO:0048304 9.5 IL4 IL2 CD28
23 regulation of T cell homeostatic proliferation GO:0046013 9.48 IL2RA IL2
24 immune response GO:0006955 9.36 TNFRSF1B IL5 IL4 IL2RA IL2 IFNG
25 regulation of regulatory T cell differentiation GO:0045589 9.35 IL2RA IL2 IFNG CTLA4 CD28

Molecular functions related to Sezary's Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.02 IL5 IL4 IL2 IFNG IFNA1
2 kinase activator activity GO:0019209 8.96 IL2 BCL10
Sources

Sources for Sezary's Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....